Abstract: Objective：To evalute the clinical application of subdermal implant Etonogestrel, so as to provide more data for the expansion of this contraceptive method. Methods: The clinical data of 81 women who volunteered to implant or take out Etonogestrel was retrospectively analyzed in our Department from January 2017 to September 2018. The adverse reactions related to Etonogestrel were collected by the centralized-telephone follow-up visit in December 2018, including the implant timing, reasons for the implantation, menstruation disturbance and treatment, the use condition and others. Results: There was no significant difference in the time of amenorrhea and irregular vaginal bleeding after implantation of Etonogestrel (P＞0.05); there were no significant differences in the causes of placement, the treatment of adverse reactions and the induced obesity between the removal group (the group A) and the using group (the group B) (all P＞0.05). However, the therapeutic effect of adverse reactions in the group B was better than that in the group A (P＜0.05). Interestingly, there was no significant difference in the removal rate between the two groups: the group of implantation for contraception and the group of implantation for the treatment of adenomyosis dysmenorrhea symptom (P＞0.05). Condom was the most common method following the removal. Conclusions: Subdermal implant Etonogestrel is a reliable contraceptive, meanwhile there is treatment effect on ameliorating dysmenorrhea symptoms of adenomyosis. The change of menstrual pattern would be limited with the prolongation of placement time. The main factor affecting the removal of Etonogestrel is the therapeutic effect of menstrual changes. Therefore, the improvement in the therapeutic effect of menstrual changes will be helpful for the extented application of subdermal implant Etonogestrel as a long-term and safe contraceptive method.

Key words: Subdermal implants, Contraceptive agents, Drug implants, Etonogestrel, Menstruation disturbances